Posted by AGORACOM-JC
at 5:22 PM on Thursday, September 23rd, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
The company recently released Q3 results and highlights:
· Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
· Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
· Record 9 months revenues at $10.2 million , up 94%.
· Private and public reimbursement coverage expanding for Redesca®
· New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
Posted by AGORACOM-JC
at 12:23 PM on Monday, July 5th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
The smile on CEO Steve Saviuk says it all. The company recently released Q2 results and highlights:
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter
Q3-21 revenues expected to increase by more than 50% over Q2-21
Redesca (blood thinner) launched in late Q2-21
Commercial shipments of the company’s asthma drugs commenced following national respiratory sales force deployment
Closed upsized $6.645 million debenture placement
Closed $11.5 million bought deal
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
Posted by AGORACOM-JC
at 8:19 AM on Friday, February 19th, 2021
Valeo will host a conference call to discuss those results and highlights on Thursday February 25, 2021 at 8.30am (EST) .
The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450.
MONTREAL , Feb. 19, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2020 on Wednesday February 24, 2021 after market close.
Valeo will host a conference call to discuss those results and highlights on Thursday February 25, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (1498873).
Posted by AGORACOM-JC
at 8:21 AM on Wednesday, February 17th, 2021
Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients
Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity
Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
Hesperco TM capsules contain 500mg of high purity concentrated hesperidin
MONTREAL , Feb. 17, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.
The MHI’s study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.
“The immune support properties of hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature. We are extremely proud to contribute in the fight against the COVID-19 virus with the prestigious MHI and our development partner Ingenew”, said Steve Saviuk , Valeo’s CEO. “Our involvement in this study aligns well with our vision to build a Canadian anchor pharmaceutical company and continued commitment to provide Canadian healthcare professionals and patients with innovative solutions to improve quality of life”.
Commenting on the Montreal Heart Institute’s Hesperidin Coronovirus Study, Pierre Laurin , President and CEO of Ingenew, said: “We are pleased that MHI’s scientists concur with our scientific findings.”
Posted by AGORACOM-JC
at 7:55 AM on Monday, January 25th, 2021
Received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO.
MONTREAL , Jan. 25, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO. “Redesca™ has a long and strong history of safety and efficacy with more than 8 years of proven in-market data internationally. Redesca™ will be available across Canada and Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies. Valeo is planning to launch Redesca™ during the first half of 2021.”
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWHs are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
Posted by AGORACOM-JC
at 7:14 AM on Monday, January 18th, 2021
Frederic Fasano named President and COO
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
Posted by AGORACOM-JC
at 12:14 PM on Thursday, January 14th, 2021
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.